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INTRODUCTION
Southeast Asia (SEA) bears a signifi cant proportion of the global 
burden of cardiovascular disease (CVD), a burden that appears 
to be increasing across the region.(1-3) In 2011, a World Health 
Organization report estimated a cardiovascular-related mortality 
rate of 3.7 million within SEA, with ischaemic heart disease and 
stroke accounting for the majority of CVD deaths.(4) The Asian 
region comprises a very heterogeneous population, which is 
evident in the differences in atherosclerotic cardiovascular disease 
(ASCVD)-related mortality reported across the region.(5) Age-
standardised mortality rates for stroke are elevated in East Asian 
countries and generally higher than those reported in Western 
countries.(6) Although East Asian countries have lower coronary 
heart disease (CHD) mortality rates than Western countries, the 
age-standardised mortality rates for CHD in South Asian and 
some SEA countries are comparable to or higher than those of 
Western countries.(7)
The link between cholesterol levels and ASCVD is 
well established.(2,3) Major risk factors for ASCVD include 
hypercholesterolaemia, hypertension, diabetes mellitus, chronic 
kidney disease (CKD), obesity and metabolic syndrome. Lifestyle, 
including smoking, physical inactivity, and excessive dietary 
consumption of fats (especially trans fat) and carbohydrates, is 
also a major contributor to the development of ASCVD.(2)
Risk factors for CVD, such as diabetes mellitus and obesity, 
have been increasing in Asia.(8) Singapore, often described 
as a microcosm of Asia as a whole, has a rapidly ageing and 
increasingly sedentary population, which predisposes individuals 
to chronic health problems faced across SEA.(5) The prevalence 
of obesity in Singapore is predicted to increase fourfold, from 
4.3% in 1990 to 15.9% in 2050. This increase is expected to be 
paralleled by an increase in type 2 diabetes mellitus (diagnosed 
and undiagnosed) from 7.3% in 1990 to 15.0% in 2050.(6) It has 
also been predicted that ethnic Indians and Malays will bear a 
disproportionate burden of disease compared with the Chinese.(5)
Experts convened in August 2014 to defi ne the landscape 
of ASCVD prevention and management in Singapore, and to 
determine the impact of current guidelines on clinical practice 
in Singapore. This review summarises the key fi ndings and 
recommendations of these guidelines, and presents key principles 
to help clinicians manage the cardiovascular risk of their patients 
more effectively. 
UNMET NEEDS IN THE PREVENTION OF 
ASCVD: A SINGAPORE PERSPECTIVE
In SEA, ageing and population growth are projected to result in 
an increase in CVD of more than 50% over the next two decades. 
Furthermore, projected unfavourable trends in blood pressure, 
total cholesterol, diabetes mellitus and body mass index may 
accelerate this epidemic.(9) Overall, ageing will prolong exposure 
to CVD risk factors and increase the CVD burden as well as 
ASCVD-related mortality and morbidity. 
The Asia Pacifi c Cohort Studies Collaboration, a meta-analysis 
of prospective observational studies in the Asia Pacifi c region 
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(29 cohorts with almost two million person-years of follow-up 
of 352,033 individuals), found a continuous positive association 
between usual cholesterol levels and risk for CHD, which 
persisted after adjustment for age, gender, blood pressure and 
smoking.(10) Each increase of 1 mmol/L in cholesterol level equated 
to approximately a 35% increase in risk of coronary death. The 
study found a weak positive association between cholesterol and 
combined risk of both fatal and nonfatal stroke (7% increase per 
1 mmol/L), but no association between total cholesterol level 
and stroke mortality.(10) 
Numerous studies have shown that statin therapy effectively 
reduces low-density lipoprotein cholesterol (LDL-C) in Asian 
patients.(11-16) However, despite the reduction of LDL-C 
following statin therapy, residual cardiovascular risk remains 
high, as illustrated by the Return on Expenditure Achieved for 
Lipid Therapy in Asia (REALITY-Asia) study.(17) A retrospective 
cohort study conducted in China, Korea, Malaysia, Singapore, 
Taiwan and Thailand (comprising 437 physicians, 41% of 
whom were cardiologists), REALITY-Asia recruited adults with 
hypercholesterolaemia who were newly initiated on statin 
monotherapy in order to examine treatment patterns, goal 
attainment and factors infl uencing treatment. The study found 
that undertreatment of patients occurred mostly in the highest-
risk group; high-risk individuals with established CHD/diabetes 
mellitus were least likely to achieve LDL-C targets than the overall 
group (38% vs. 48% goal attainment). Despite considerable 
baseline cardiovascular risk, 89% of patients received statins 
at low or moderate equipotent doses; the majority were using 
low-intensity statins.(17) The REALITY-Asia fi ndings highlighted 
the presence of statin phobia at the regional, country, physician 
and patient levels.(17) Factors associated with a signifi cantly 
increased likelihood of goal attainment included advanced age 
and treatment with high-potency statins, whereas increased 
cardiovascular risk for CHD/diabetes mellitus at baseline (as 
compared with less than two risk factors) and baseline LDL-C 
levels were inversely associated with LDL-C goal achievement.(17)
In Singapore, approximately 47% of patients used low-
potency statins, the majority of which were prescribed by general 
practitioners; of these patients, 45% required up-titration.(18) In 
particular, 40%–60% of diabetic patients required up-titration, 
but there was reluctance to up-titrate or switch to a higher dose 
or higher potency statin. A number of studies have highlighted 
that Asian patients with CVD are not achieving their target lipid 
goals despite statin therapy.(19-21) Data from the Achievement in 
Singapore of Cholesterol Targets study confi rmed that, in a cohort 
of over 5,000 CHD patients, most who were considered to be 
at high risk did not achieve the recommended LDL-C targets.(19)
ASSESSMENT AND TREATMENT OF 
ASCVD RISK
Lipid proﬁ le
While the 2013 American College of Cardiology/American Heart 
Association (ACC/AHA) Cholesterol Treatment Guidelines(22) 
still use LDL-C levels to classify the degrees of risk for primary 
prevention of ASCVD, the updated 2014 National Institute for 
Health and Care Excellence (NICE) guidelines recommend the 
use of non-high-density lipoprotein cholesterol (HDL-C), as 
it is a better predictor of risk than LDL-C.(23) Specifi cally, the 
NICE guidelines recommend the measurement of non-fasting 
lipid profi le, namely total cholesterol, HDL-C, non-HDL-C and 
triglycerides, before the initiation of lipid modifi cation therapy. 
Treatment recommendations are, however, based on statin 
intensity rather than LDL-C or non-HDL-C targets.(23) When a 
target reduction of > 40% non-HDL-C is required, high-intensity 
statin therapy should be initiated. Although the defi nitions of 
low-, moderate- and high-intensity statin therapy are still based 
on estimations of LDL-C reduction, they differ slightly between 
the ACC/AHA and NICE guidelines (Table I).(22,23) It should also 
be noted that the only recommended high-intensity statins are 
atorvastatin and rosuvastatin. For moderate- and low-intensity 
statin therapy, simvastatin, fl uvastatin, lovastatin, pravastatin 
and pitavastatin together with lower doses of atorvastatin and 
rosuvastatin (only for moderate intensity) are recommended. 
Atorvastatin and rosuvastatin do not have a recommendation for 
low-intensity therapy.
ASCVD risk scoring
The 2013 ACC/AHA cholesterol guidelines have adopted a 
broader focus on ASCVD risk (including CHD and stroke). The 
Pooled Cohort Equations risk calculator was used to assess the ten-
year risk.(22) These guidelines identify four groups of patients who 
will benefi t from statin treatment: patients who have (a) clinical 
ASCVD (i.e. history of myocardial infarction [MI], stable angina, 
acute coronary syndrome [ACS], stroke, transient ischaemic attack, 
peripheral vascular disease) – secondary prevention; (b) familial 
hypercholesterolaemia with LDL-C ≥ 190 mg/dL – primary 
prevention; (c) diabetes mellitus (age 40–75 years) with LDL-C of 
70–189 mg/dL – primary prevention; and (d) LDL-C of 70–189 
mg/dL with a ten-year ASCVD risk ≥ 7.5% – primary prevention.
The NICE guidelines also advocate initiating statin therapy 
based on CVD risk.(23) In the updated 2014 guidelines, the 
Table I. Statin-intensity approach to treatment.(22,23)
Parameter Intensity level
High Moderate Low
Statin (mg)
Atorvastatin 20*–80 10–20* ―
Rosuvastatin 20–40 5–10 ―
Simvastatin ― 20–40 10
Fluvastatin ― 80 (× 2) 20–40
Lovastatin ― 40 20
Pravastatin ― 40–80 10–20
Pitavastatin ― 2–4 1
LDL reduction (%)
 ACC/AHA 2013(22) ≥ 50 30–< 50 < 30
 NICE 2014(23) > 40 31–40 20–30
*20 mg atorvastatin is considered high-intensity according to the National 
Institute for 2014 Health and Care Excellence (NICE) guidelines, but is 
moderate-intensity according to the 2013 American College of Cardiology/
American Heart Association (ACC/AHA) guidelines
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threshold for starting preventive treatment with statins has been 
reduced from a risk of 20% to 10% over ten years.(23) The NICE 
guidelines also recommend that CVD risk should be assessed 
using the QRISK2 assessment tool, which calculates the ten-year 
risks of MI and stroke based on 140,000 cardiovascular events 
in 2.3 million British patients (including different ethnic groups 
such as Chinese and South Asians).
A recent review of cardiovascular assessment tools confi rms 
that global risk assessment is essential for targeted, aggressive risk 
factor management.(24) However, few CVD risk assessment tools 
have been developed in Asian countries for Asian populations, 
underscoring the need for an Asian-specifi c risk-assessment tool to 
accurately predict cardiovascular risk in Asian patients.(24) Studies 
have found that the predictability of CVD risk scores, which 
were developed mainly for Caucasians, varies considerably, 
mainly due to overestimating the risks of MI in East Asians and 
underestimating lifetime risk among South Asians.(25) It is probably 
safe to assume that the same is true for Singapore. A number of 
factors have been proposed to explain this. Firstly, data regarding 
incident CVD mortality, morbidity and risk factor prevalence 
in most East and South Asian populations is inadequate, thus 
preventing accurate calibration of a CVD risk score derived 
from another population. In addition, there is a lack of local 
longitudinal cohort data to supply robust information on the 
relationship between CVD risk factors and outcomes.(25) 
GUIDELINE RECOMMENDATIONS FOR 
ASCVD PREVENTION 
A number of local and international guidelines on CVD have 
been published.(22,23,26-29) Each set of guidelines provides differing 
recommendations advocating a treat-to-target approach, a statin 
intensity-centric approach, or a combination of the LDL-C target 
and statin-centric approaches. In most of the current international 
guidelines, treatment targets have been eliminated; instead of 
a target-based approach, the new guidelines take a drug- and 
dose-based approach. The 2013 ACC/AHA cholesterol treatment 
guidelines emphasise that treatment decisions must be based on 
physician-patient discussion and that treatment may be indicated 
for some patients who are not in the four categories.(22) The panel 
noted that with regard to key recommendations for statin therapy 
in the treatment and prevention of ASCVD, the role of statin 
therapy in the treatment paradigm for coronary artery disease 
differs among patient populations, and should therefore include 
both statin- and LDL-centric approaches, especially for patients 
in the high- and very-high-risk groups.(22)
Statin- versus LDL-centric approach
The 2013 ACC/AHA cholesterol treatment guidelines adopt 
a statin-centric approach, disregarding LDL goals(22) and 
discouraging the use of non-statin drugs that do not reduce the 
risk of events in statin-treated patients. However, this approach 
has been challenged by the fi ndings of the IMProved Reduction 
of Outcomes: Vytorin Effi cacy International Trial (IMPROVE-IT), 
which investigated the simvastatin/ezetimibe combination in high-
risk post-ACS patients and provided evidence that lower LDL-C 
levels were more benefi cial (target LDL level < 55 mg/dL).(30) 
However, IMPROVE-IT showed that even with the addition of 
ezetimibe to simvastatin 40 mg, LDL-C levels decreased by only 
40%, whereas the guidelines recommend a reduction of at least 
50% for this patient population.(22,23) 
The revised 2015 American Diabetes Association (ADA) 
Standards of Medical Care in Diabetes guidelines have also 
adopted recommendations from the 2013 ACC/AHA guidelines 
for cholesterol management in diabetics, in which high-intensity 
statins were recommended for all diabetic patients with increased 
cardiovascular risk.(28) In contrast, European guidelines for CVD 
prevention recommend treating to target cholesterol levels: LDL-C 
< 115 mg/dL (< 3 mmol/L) for subjects at low or moderate risk; 
LDL-C < 100 mg/dL (< 2.5 mmol/L) for high-risk patients; and 
LDL-C < 70 mg/dL (< 1.8 mmol/L) for very-high-risk patients.(26) 
Furthermore, they recommend that patients with ACS should be 
started on high-intensity statin therapy in hospital.(26) The recently 
published 2015 European Society of Cardiology guidelines 
for ACS without persistent ST segment elevation (NSTE-ACS), 
however, recommend the initiation of high-intensity statin therapy 
(i.e. statin regimens that reduce LDL-C by about 50%) as early as 
possible after admission for all NSTE-ACS patients.(29)
The current Singapore Clinical Practice Guidelines (CPG) on 
Diabetes Mellitus also advocate an LDL-centric approach for the 
prevention of ASCVD in diabetes mellitus.(27) For the majority of 
patients with type 2 diabetes mellitus, where LDL-C is > 100 mg/dL 
(> 2.6 mmol/L), statin therapy should be started concurrently with 
therapeutic lifestyle modifi cation. While the local guideline 
generally refl ects the current practice, it also recognises that not all 
cases of diabetes mellitus should be considered a cardiovascular 
risk equivalent; it includes a category allowing for a period of 
lifestyle intervention without statin therapy in patients deemed 
to be at low risk. Although a number of recommendations are 
based on expert consensus, limited local objective evidence 
is available to support them. Based on the Singapore CPG on 
Diabetes Mellitus, in individuals without overt CVD, the goal is 
LDL-C < 100 mg/dL, while in individuals with overt CVD or CKD, 
a lower LDL-C goal of < 82 mg/dL (2.1 mmol/L) is advised.(27) In 
a subgroup of patients with high LDL-C (> 2.3 mmol/L) and low 
HDL-C (< 0.88 mmol/L), statin-fenofi brate combination therapy 
may be benefi cial.(27)  
Despite the trend of population ageing, both within SEA 
and globally, there are no recommendations for the elderly 
aged > 75 years or regarding the impact of the risk of CKD on 
prescribing decisions due to the lack of evidence in these patient 
populations. As guidelines are developed according to rigorous 
criteria such as requiring strong clinical trial evidence as a basis 
for recommendations, this lack of evidence prevented their 
development. 
The Kidney Disease – Improving Global Outcomes (KDIGO) 
2013 guidelines(31) highlight the limitations of LDL-C as a marker 
of cardiovascular risk in CKD and urge caution in using changes 
in LDL-C as a gauge for prescribing statins to patients with CKD. 
There is no on-treatment LDL-C target for CKD patients who 
are not on chronic dialysis or kidney transplantation; KDIGO 
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recommends statin therapy as secondary ASCVD prevention for 
patients aged 18−49 years with one or more of the following: 
prior CHD; diabetes mellitus; or prior ischaemic stroke. A statin 
with or without ezetimibe, according to age, diabetes mellitus 
and estimated glomerular fi ltration rate (eGFR), is recommended 
for primary prevention of ASCVD.(31) 
Current treatment practice in Singapore: are clinicians 
underdosing high-risk patients? 
In clinical trials, such as the Incremental Decrease in End Points 
Through Aggressive Lipid Lowering and Treating to New Targets 
studies,(32,33) different doses of statins were studied and LDL-C 
levels were evaluated to ensure that the correct dose was used 
to avoid undertreatment. Most of the studies selected individuals 
with an existing clinical condition and treated them with fi xed-
dose statins (e.g. high- vs. low-intensity or statin vs. placebo). 
None of the trials targeted a specifi c LDL-C level and there was 
no provision for dose up-titration. However, in clinical practice, 
there is a strong reluctance for treatment based on statin intensity 
(e.g. high-intensity statins are better than low-intensity statins 
[Table I]) as opposed to the LDL-centric approach.
 In Asia, there are many challenges in adopting the ACC/
AHA 2013 guidelines. Evidence indicates that Chinese patients 
have a higher incidence of myopathy at much lower statin 
doses.(34) Consequently, there is reluctance to use high-intensity 
statins at the maximum dose. The ACC/AHA Pooled Cohort 
Equations risk assessment is unsuitable for Asian populations, 
as patients from this region were not included during the 
development of the tool.(22) Recent guidelines also recommend 
treating risk rather than LDL-C levels.(22,23) In Singapore, there are 
many high-risk patients who are not on high-intensity statins, 
as there is a perception that Asians are intolerant to statins.(35) 
Anecdotal evidence suggests that in Singapore, there is concern 
among both physicians and patients regarding intensifying statins; 
both groups are averse to using high-intensity statins and prefer 
dose reduction once LDL-C levels fall below 70 mg/dL. Increased 
understanding of the pathogenesis of ASCVD has underscored 
the importance of treating both risk factors and LDL-C levels. 
Clinicians should consider the evidence in favour of reducing 
LDL-C levels in young, high-risk individuals with heterozygous 
familial hypercholesterolaemia in order to achieve maximal 
long-term cardiovascular benefi ts. However, it is a challenge to 
convince Asian doctors and patients to adopt this approach.
Asians are more susceptible to adverse effects of high-
intensity statins: evidence or opinion?
Available data indicates that the effect of statins in Asian patients 
is not a class effect. For atorvastatin, similar pharmacokinetics 
in Asians and Caucasians predict a correlation between effi cacy 
and safety in Asian and global studies, supporting similar dosing 
regimens in these populations.(36) In contrast, systemic exposure 
to rosuvastatin is higher in Asians compared with Caucasians;(37) 
signifi cant differences in pharmacokinetics between these patient 
populations predict a lack of correlation between effi cacy and safety. 
Consequently, prescribing information for rosuvastatin recommends 
the same low starting dose (5 mg) in Asians as in patients with renal 
impairment.(38) Emerging data also suggests that rosuvastatin may 
have an adverse effect on renal function, with signifi cant reductions 
in eGFR observed in patients with type 1 or 2 diabetes mellitus.(39)
Evidence confi rms that the adverse effects of atorvastatin are 
similar across the dose range.(36,37) The IRIS trial involving patients 
of South Asian origin with CHD also showed a dose-dependent 
reduction in LDL-C with atorvastatin and a comparable safety profi le 
in both arms of the study (i.e. atorvastatin 10 mg and 20 mg).(36) 
Unlike atorvastatin, simvastatin was associated with a higher risk 
of myopathy in a large cohort of Chinese patients, as compared 
with Caucasian patients (n = 25,673).(34) The absolute risk of any 
myopathy (defi nite or incipient) was much higher in China than in 
Europe (0.13%/year vs. 0.04%/year; p = 0.001). Recently reported 
fi ndings from the Heart Protection Study 2 – Treatment of HDL to 
Reduce the Incidence of Vascular Events (HPS2-THRIVE), which 
showed a higher rate of myopathy in the Chinese population,(34) 
have led to new precautions, including advising caution when 
prescribing simvastatin to Asian patients and that the lowest dose 
necessary should be employed. Although Chinese patients were 
the only Asians assessed in HPS2-THRIVE and data on other Asian 
populations is limited, the manufacturer has proposed that these 
new precautions for simvastatin use be extended to all Asians, 
including Japanese, Malays and Asian-Indians, due to the potential 
seriousness of myopathy. Therefore, the Health Sciences Authority, 
Singapore, has recommended updating local package inserts of 
products containing simvastatin to provide new recommendations 
for the use of simvastatin in Asians.(40)
Expert opinions and recommendations for ideal clinical 
practice in Singapore
There are currently a number of international and local guidelines 
that advocate different approaches to ASCVD prevention and 
management.(22,23,26-29) The local CPG on diabetes mellitus remains 
LDL-centric,(27) in contrast to recent guidelines, such as ACC/AHA 
2013 and ADA 2015, that recommend high-intensity statins for 
primary prevention in high-risk diabetic patients.(22,28) NICE 2014 
recommends atorvastatin 20 mg (i.e. high-intensity according 
to NICE) for primary prevention of CVD and atorvastatin 80 mg 
for secondary prevention in patients with CVD.(23) In Singapore, 
there is a clear need for a standard multidisciplinary consensus 
on lipid-lowering treatment that is specifi c to the local population 
and includes the modifi ed Singapore Framingham risk score. 
Meanwhile, this expert panel identifi ed some common principles 
to consider when treating patients at risk of ASCVD.
Risk prediction scoring tool
Assessment of ASCVD risk is important and Asian-specifi c risk 
assessment tools (risk calculators) should be used when available. 
Anecdotal evidence suggests that the ASCVD risk calculator is 
underutilised among Asians. Ideally, each country should develop 
a risk calculator that is applicable to its population or recalibrate 
existing international risk calculators. If one is not available, the 
QRISK2 calculator may be a better option for Asians than the 
ACC/AHA Pooled Cohort Equations, as it incorporates Asian 
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ethnic groups (e.g. Chinese, Indian, Pakistani, Bangladeshi, other 
Asians), CKD, atrial fi brillation (AF), rheumatoid arthritis (RA) and 
body mass index.(23) The JBS3 calculator, produced by the Joint 
British Societies for the prevention of CVD, included estimations 
of lifetime risk, which may enable a more accurate ASCVD risk 
assessment.(41) However, the effectiveness of the JBS3 calculator 
to assess risk in the Asian population remains to be determined.
Lifestyle modification 
The panel concurred that lifestyle modifi cations may be employed 
in patients at low risk of CVD. This recommendation is in 
agreement with the local guidelines, which allow for a period of 
lifestyle intervention without statin therapy in patients who are 
considered low-risk.(28)
Low- verses high-intensity statin 
Ideally, clinicians should aim for LDL-C targets based on the 
National Cholesterol Education Program’s Adult Treatment 
Panel III guidelines.(42) However, as this approach may result 
in undertreatment of many patients, a risk-based approach 
may be more appropriate. Furthermore, it is important to start 
statin therapy at the intended dose. In the Asian population, 
atorvastatin 10–20 mg is suitable for primary prevention, while 
40–80 mg should be considered for secondary prevention 
(achieving > 50% LDL-C reduction). Rosuvastatin 10 mg and 
20 mg (up to 40 mg) can also be considered for primary and 
secondary prevention, respectively. Higher statin doses that will 
produce lower LDL-C levels should be adhered to in patients with 
overt CVD. Commencing statins and continuing on long-term 
statin therapy in younger high-risk individuals (e.g. those with 
heterozygous familial hypercholesterolaemia) may confer greater 
cardiovascular benefi ts than initiating treatment at an older age. 
Evidence shows that atorvastatin has a similar tolerability profi le 
in Asian and Caucasian patients. However, consideration should 
be given to the recent fi ndings of the HPS2-THRIVE study when 
prescribing high-intensity simvastatin to Asian patients.
Based on the above, it is evident that the Singapore 
ASCVD expert group has assimilated the most appropriate 
recommendations from the various current guidelines for the 
following population subgroups (Table II): 
1. Patients with established ASCVD, e.g. CHD, history of 
MI, stable angina, ACS (i.e. unstable angina, non-ST 
segment elevation MI, ST segment elevation MI, stroke, 
transient ischaemic attack and peripheral arterial disease) 
as secondary prevention.
(a) High-intensity statins are usually required to achieve 
maximal cholesterol lowering of ≥ 50% LDL-C 
reduction, although it is recognised that there may be 
inter-individual variations in the response to LDL-C 
reduction with a fi xed dose of statin.
(b) Atorvastatin 40–80 mg or rosuvastatin 20–40 mg 
reduce LDL-C by an average of ≥ 50%. 
(c) There is still a role for an LDL-centric approach; LDL-C 
should be lowered to very low levels (preferably 
≤ 70 mg/dL). 
(d) Based on current evidence,(30) in very-high-risk patients 
who are unable to achieve ≥ 50% LDL-C reduction 
or are not on LDL target ≤ 70 mg/dL, the addition of 
ezetimibe can be considered; recently, proprotein 
convertase subtilisin/kexin type 9 (PCSK9) monoclonal 
antibodies have also been recommended.(43) 
2. Patients with familial hypercholesterolaemia, with LDL-C 
≥ 190 mg/dL.
(a) High-intensity statins are required to lower LDL-C as 
much as possible.  
(b) The addition of a non-statin drug (e.g. ezetimibe) 
may be required to further lower LDL-C levels. 
These recommendations are based on the fact that 
individuals with LDL-C ≥ 190 mg/dL, even without 
risk factors, have a high lifetime risk of ASCVD.
(c) PCSK9 inhibitors have recently received the approval 
of the United States Food and Drug Administration for 
the treatment of familial hypercholesterolaemia.(43)
3. Diabetes mellitus (type 1 or 2) patients aged 40–75 years, 
with LDL-C of 70–189 mg/dL.
(a) There is almost universal agreement that diabetic 
patients with established ASCVD should receive high-
intensity statin therapy to achieve maximal LDL-C 
lowering of ≥ 50% in order to attain very low levels of 
LDL-C (≤ 70 mg/dL).(23) Based on the current consensus, 
if patients cannot achieve ≥ 50% LDL-C reduction or 
are not on an LDL-C target ≤ 70 mg/dl, the addition of 
ezetimibe or PCSK9 inhibitors can be considered.
(b) Primary prevention
 i.  In patients who are categorised as high-risk (ASCVD 
pool cohort ≥ 7.5% or QRISK2/JBS3 ≥ 10%), high-
intensity statin therapy can be considered. For those 
in the moderate-risk category (ASCVD < 7.5% or 
QRISK2/JBS3 < 10%), moderate-intensity statin 
therapy can be considered. 
 ii.  For patients with a residual risk burden (especially 
high triglycerides ≥ 200 mg/dL, HDL-C < 40 mg/dL), 
the addition of a fi brate after the commencement 
of statin therapy can be considered.
4. Patients aged 40–75 years, with LDL-C of 70–189 mg/dL, 
as primary prevention.
(a) Individuals in this category have numerous complex 
issues depending on their risk profi le. 
(b) Global risk assessment using the risk calculator is 
required, with categorisation to high- or moderate-
risk for initiation of high- or moderate-intensity statin 
therapy (refer to 3bi & ii). 
5. CKD patients.
(a) Assessment and classifi cation of CKD stage is required 
using the KDIGO eGFR nomenclature.(28) 
(b) LDL-C targets should be avoided due to the poor 
correlation of LDL-C levels with CVD risk. There 
is a paradoxical association between cholesterol 
and cardiovascular outcomes, especially in patients 
with end-stage renal disease who require dialysis, 
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due to confounding factors such as malnutrition, 
infl ammation and the effect of modifi cation by protein 
energy wasting, which lower the LDL-C. Additionally, 
advanced kidney failure patients with low cholesterol, 
who are at high risk, are often not identifi ed. 
(c) Statin-naïve patients on dialysis do not appear to 
benefi t from the initiation of statin therapy (similar to 
heart failure class II–IV).  
(d) All CKD patients who are not on dialysis are at high risk 
for ASCVD and should be given moderate-intensity 
statin therapy (refer to 3bi & ii). Dialysis and renal 
transplant patients who are already on statin therapy 
should remain on it.
(e) Moderate-intensity statins are recommended for 
advanced CKD patients to avoid the high risk of 
medication-related adverse events because of reduced 
renal excretion, frequent polypharmacy and high 
prevalence of comorbidities.  
(f) Combination therapy with a non-statin (e.g. ezetimibe) 
is useful for avoiding high-intensity statin therapy to 
attain the desired LDL-C reduction. 
(g) Statin therapy is appropriate in adult kidney transplant 
recipients. However, toxicity due to drug interactions, 
especially with calcineurin inhibitors, needs to be 
taken into account.(44) A low starting dose with cautious 
increments, according to patient tolerability and 
indication, is recommended.
CONCLUSION
Increased understanding of the pathogenesis of ASCVD has 
underscored the importance of treating both risk factors and 
LDL-C levels. Recent guidelines are in favour of treating CVD 
risks rather than targeting specifi c LDL-C levels. At present, there 
are no consolidated guidelines and risk assessment tools for 
ASCVD management in Singapore. Hence, physicians must rely 
on clinical judgement to make best practice decisions for their 
patients. Additionally, there are concerns among both physicians 
and patients in Singapore regarding intensifying statins, as there is 
a perception that Asians are less tolerant to high-intensity statins. 
Consequently, many high-risk patients are not on high-intensity 
statins, despite evidence confi rming that the effi cacy and safety of 
certain statins (e.g. atorvastatin) are similar in Asian and Caucasian 
patients across the dose range. Therefore, a locally developed 
and validated risk assessment tool is needed to guide treatment 
decisions for Singapore physicians.
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